Patients must not have any co-existing condition that would preclude full compliance with the study; no prior history of severe hypersensitivity reaction to docetaxel or other drugs formulated with polysorbate 80
Known allergies, hypersensitivity, or intolerance to any of the study medications, excipients, or similar compounds.
Patients with hypersensitivity to albumin are not eligible
Known hypersensitivity to 5-fluorouracil/leucovorin
Known hypersensitivity to irinotecan
Known hypersensitivity to any component of bevacizumab
Patients with a known hypersensitivity to olaparib or any of the excipients of the product
Patients with a known hypersensitivity to the combination/comparator agent
Known hypersensitivity to any of the study drugs or excipients, e.g., polysorbate 80 and Cremophor EL
Patients must not have any known previous or concurrent condition suggesting susceptibility to hypersensitivity or allergic reactions, including, but not limited to: known hypersensitivity to any of the study treatments or to excipients of recombinant human or humanized antibodies; patients with mild or seasonal allergies may be included after discussion with the study chairs
Patients must not have any history of hypersensitivity to any drugs or metabolites of midostaurin
Any previous treatment with a PARP inhibitor, including olaparib and/or known hypersensitivity to any of the excipients of study treatment
No history of hypersensitivity active or inactive excipients of osimertinib or drugs with a similar chemical structure or class to osimertinib
No known history of severe hypersensitivity reactions to any of the components of efatutazone or paclitaxel formulations
Patients with known hypersensitivity to any TZD oral agents are not eligible
Patients with a history of hypersensitivity reactions to prior chemotherapy administered for previous cancer diagnoses are eligible to participate in the study, unless the hypersensitivity reaction consisted of anaphylaxis not amenable to desensitization
Known hypersensitivity to any component of the formulation or substituted benzimidazoles
Known intolerance to either of the study drugs (or any of the excipients)
Patient has a known hypersensitivity to any of the components of the study drug
Patients with a known hypersensitivity to olaparib, temozolomide or any of the excipients of the products
Patients with a history of hypersensitivity to nickel
Patients with known hypersensitivity to any component of the chemotherapy regimen will not be eligible
Known hypersensitivity to gemcitabine, azacytidine or cytosine arabinoside
Known hypersensitivity to any component of bevacizumab
Known hypersensitivity to any oligodeoxynucleotide.
Patients with a known hypersensitivity to olaparib or any of the excipients of the product
History of hypersensitivity to active or inactive excipients of AZD5363, fulvestrant and enzalutamide or drugs with a similar chemical structure or class to these agents
Hypersensitivity to nivolumab, ipilimumab, or any of their excipients
Known prior severe hypersensitivity to investigational product or any component in its formulations, including known severe hypersensitivity reactions to monoclonal antibodies (NCI CTCAE v4.03 grade >= 3) that could interfere with study endpoints or put patient safety at risk
Known hypersensitivity to any of the excipients of ribociclib
Prior history of hypersensitivity, drug or radiation-induced, or other immune-mediated pneumonitis
Known hypersensitivity to any component of the atezolizumab or cobimetinib formulations
Documented progression on and/or intolerance/hypersensitivity to both paclitaxel and irinotecan (Part B only)
History of hypersensitivity to any of the additives in the alectinib drug formulation
Hypersensitivity to pembrolizumab or history of severe allergic or hypersensitivity reactions to excipients (e.g., polyethylene glycol [PEG] 300 and polysorbate 80)
Hypersensitivity to carboplatin or cisplatin
Known hypersensitivity to the components of MM-310, or docetaxel
History of prior >= grade 3 hypersensitivity to either brentuximab vedotin or nivolumab
Known hypersensitivity to Apatinib or components of the formulation.
Known hypersensitivity to any of the study drugs
History of hypersensitivity to durvalumab or tremelimumab or any excipients of these drugs.
Known hypersensitivity to any study drug component
Subject with a history of severe hypersensitivity reactions to any of the other excipients of the protocol IMPs (see Section 8.1.1);
Hypersensitivity to the active substance or to any of the excipients
Known hypersensitivity to any component of required drugs in the study
Known hypersensitivity to any of the components of RO6874281
For Part B exclusively, known hypersensitivity to any of the components of trastuzumab
For Part C exclusively, known hypersensitivity to any of the components of cetuximab
Patients with a known hypersensitivity to olaparib or any of the excipients of the product
Patients with a known hypersensitivity to the combination/comparator agent
Hypersensitivity to taxanes (such as Steven Johnson syndrome). Hypersensitivity, such as rash < Grade 3 that is managed, is allowed.
Patients with a known hypersensitivity to everolimus or other rapamycins (sirolimus, temsirolimus) or to its excipients
Patients with a known hypersensitivity to carboplatin
Patient has a known hypersensitivity to any of the excipients of LEE011
Patient has a known hypersensitivity to ribociclib or any of its excipients, or prior treatment with CDK 4/6 inhibitor
Hypersensitivity to:
History of hypersensitivity to iodine
Known intolerance or hypersensitivity to everolimus or other rapamycin analogs (e.g. sirolimus, temsirolimus)
Subjects with a known hypersensitivity to everolimus or other rapamycins (sirolimus, temsirolimus) or to its excipients
Patients with known hypersensitivity to any of the components of CBL0137;
Known hypersensitivity to drugs chemically related to tivozanib hydrochloride or sunitinib or their excipients
Known hypersensitivity to sunitinib or masitinib or to any of the excipients
Known hypersensitivity to afatinib, cisplatin, or pemetrexed
Patients who have had hypersensitivity to paclitaxel or any of its excipients
Subjects with a hypersensitivity to sirolimus.
Has a known severe hypersensitivity (? Grade 3) to any of the study chemotherapy agents and/or to any of their excipients.
Have previously participated in any study involving a checkpoint kinase 1 inhibitor or have hypersensitivity to the study drug or excipients.
Known hypersensitivity to the components of niraparib components or their formulation excipients
Prior exposure to a pyrrolobenzodiazepine or indolino-benzodiazepine based drug, or known hypersensitivity or contraindication to SC-005 or excipient contained in the drug formulation.
Previously identified hypersensitivity to components of the formulations used in this study
Known hypersensitivity to exemestane or its excipients
Hypersensitivity to nivolumab or any of its excipients.
Hypersensitivity to NKTR-214 or any of its excipients.
No history of severe hypersensitivity reaction to Cremophor EL
Participant has a known hypersensitivity to any of the excipients of H3B-6545.
Known hypersensitivity to ferumoxytol or any of its components
Known intolerance to study drug (or any of the excipients) and/or known hypersensitivity to rapamycins (eg, sirolimus, everolimus, temsirolimus) or any of the excipients
Known hypersensitivity to one or more of the study agents used
Patient has a known hypersensitivity to any of the excipients of ribociclib or everolimus
Known hypersensitivity to any study related agent excipient(s)
Known hypersensitivity to platinum compounds
Those with porphyria or with known hypersensitivity to porphyrins or porphyrin-like compounds
Documented hypersensitivity reaction to any product with GSE
History of, or known, hypersensitivity to any components of melphalan or the components of the Melphalan/HDS system.
History of, or known, hypersensitivity to gemcitabine or platinum-containing compounds.
Subjects with known allergies, hypersensitivity, or intolerance to niraparib or its excipients
History of hypersensitivity to tremelimumab, durvalumab, or any excipient
Patient has a known hypersensitivity to any of the excipients of LEE011 or everolimus
Prior hypersensitivity to any of the components of the study drugs
Known hypersensitivity to afatinib or the excipients of any of the trial drugs
Patients with a known hypersensitivity to everolimus or other rapamycins (e.g. sirolimus, temsirolimus)
Patients with hypersensitivity to bortezomib, boron or mannitol.
Combination Arm: hypersensitivity to trastuzumab
Known hypersensitivity to gemcitabine, taxanes or any of their excipients, or the patient exhibits any of the events outlined in the Contraindications or Special Warnings and Precautions sections of the product or comparator Summary of Product Characteristics or Prescribing Information. Possible hypersensitivity to napabucasin or one of the excipients which include the azo dyes sunset yellow and allura red.
History of severe hypersensitivity to study treatment excipients and additives or other monoclonal antibodies (mAbs) and/or their excipients.
Porphyria or known hypersensitivity to Photofrin® or porphyrin-like compounds or to any of its excipients
History of life-threatening hypersensitivity to monoclonal antibodies or to recombinant proteins or excipients in drug formulation
History of hypersensitivity to sertraline
Patients must not be known to have hypersensitivity to cisplatin, gemcitabine, or celecoxib
Patients with a known hypersensitivity to any excipient contained in the drug formulation
Any history of hypersensitivity to irinotecan
History of hypersensitivity to durvalumab or any excipient
History of hypersensitivity to tremelimumab or any excipient
Patients with known hypersensitivity to any of the excipients of INC280 (crospovidone, mannitol, microcrystalline cellulose, povidone, sodium lauryl sulfate, magnesium stearate, colloidal silicon dioxide, and various coating premixes)
History of hypersensitivity to AZD4635 or drugs with a similar chemical structure or class to AZD4635.
Participants with known allergies, hypersensitivity, or intolerance to ibrutinib or its excipients (refer to Investigator's Brochure)
Patients with known hypersensitivity to any of the components of the PEGylated AuroShell suspension (polyethylene glycol, gold)
Prior known hypersensitivity to any of the excipients of alpelisib
Known hypersensitivity to immunoglobulins or to any other component of the IP formulation
Participants who have a history of hypersensitivity reactions to paclitaxel or other drugs formulated in Cremophor® EL (polyoxyethylated castor oil) or to nab-paclitaxel and any of the excipients
Known hypersensitivity to thalidomide or lenalidomide
Known hypersensitivity to Velcade, boron, or mannitol
Have known hypersensitivity to platinum compounds or gemcitabine.
Patients with a known hypersensitivity to tacrolimus, methotrexate (Arm A or C) or MMF (Arm B or D)
Known history, or suspected hypersensitivity to any excipients.
History of known hypersensitivity to cetuximab, docetaxel or similar agents
Known hypersensitivity to the metal in the electrodes (stainless steel 304 L) that cannot be medically managed
Known hypersensitivity to orteronel or to orteronel excipients, which are listed by formulation in the Investigator Brochure
Known or suspected hypersensitivity to 5-azacitidine or mannitol
Part B only: Hypersensitivity to study drugs given in combination with LY3023414
Known hypersensitivity to any of the components of the study drugs
Known hypersensitivity to methotrexate
No known hypersensitivity to trastuzumab
Any known hypersensitivity to bevacizumab, erlotinib or other excipients of these drugs
Patients with a known hypersensitivity to treosulfan and/or fludarabine
Known hypersensitivity to any of the components of M7824 or eribulin.
Known hypersensitivity to thalidomide.
EXCLUSION - PARTICIPANT: Participants with a history of hypersensitivity reactions to study agent or their excipients.
Has a history of hypersensitivity to durvalumab or tremelimumab excipient
Hypersensitivity to IV contrast; not suitable for pre-medication
Previously known hypersensitivity to any of the agents used in this study; known sensitivity to melphalan
Patients with known hypersensitivity to any of the excipients of ceritinib (microcrystalline cellulose, mannitol, crospovidone, colloidal silicon dioxide and magnesium stearate)
Known hypersensitivity to bortezomib, ixazomib, dexamethasone, or ONC201
History of hypersensitivity to durvalumab, tremelimumab or any excipient.
Known hypersensitivity to any of the study drugs
The patient has known hypersensitivity to gelatin or lactose monohydrate
Proven hypersensitivity to statins
Known severe hypersensitivity to gemcitabine
Subjects with a known hypersensitivity to olaparib or any of the excipients of the product.
Known hypersensitivity to any of the components of LMB-100 and/or SEL-110
Known allergies, hypersensitivity or intolerance to apalutamide, abiraterone acetate, prednisone, or GNRH agonist or GNRH antagonist
History of hypersensitivity to active or inactive excipients of osimertinib or drugs with a similar chemical structure or class to osimertinib
Participants must not have hypersensitivity to nivolumab, urelumab, cabiralizumab or any of their excipients
History of hypersensitivity to cyclophosphamide, fludarabine, dimethyl sulfoxide (DMSO) or IL-2
Known hypersensitivity to any of the study drugs
Known hypersensitivity to any of the study drugs or analogs
Known prior severe hypersensitivity to investigational product or any component in its formulations, including known severe hypersensitivity reactions to monoclonal antibodies (National Cancer Institute [NCI] CTCAE v5.0 grade >= 3)
Has severe hypersensitivity (?Grade 3) to any study therapies including any excipients
Hypersensitivity to Ipilimumab and/or nivolumab or any of its excipients
Known hypersensitivity to gemcitabine (or other drug excipients) or chemically related drugs.
Known hypersensitivity to the device constituent or TARIS Inserter materials.
Has known hypersensitivity to either the drug substances or inactive ingredients in the drug product
Known hypersensitivity/intolerance to capecitabine, infusional 5-flurouracil, or bevacizumab
Subject has known sensitivity and immediate hypersensitivity to any components of AMG 119 or conditioning regimen (cyclophosphamide and fludarabine).
Known allergies, hypersensitivity, or intolerance to erdafitinib or its excipients
History of severe hypersensitivity reactions to components of the cobimetinib, atezolizumab, or pembrolizumab formulations
Known intolerance or hypersensitivity to any of the products used in this study or their excipients.
Known hypersensitivity to any component of study drug including potential subjects with a history of major immunologic reaction to any IgG-containing agent
History of hypersensitivity to AZD9291 (or drugs with a similar chemical structure or class to AZD9291) or any excipients of these agents
Subjects with known hypersensitivity to study drugs or their excipients
Known hypersensitivity to nintedanib, nivolumab, ipilimumab, peanut or soy or any other trial drug, or their excipients
Previous hypersensitivity to rapamycin or rapamycin derivatives
Known allergies, hypersensitivity, or intolerance to any of the study medications, excipients, or similar compounds
Hypersensitivity (not including renal dysfunction or eye disorder) to CDV or to BCV or its formulation excipients
Patient has a known history of hypersensitivity to defibrotide or any of the excipients.
Carotid sinus hypersensitivity syndrome.
History of clinical hypersensitivity to the immunotherapy proposed for combination treatment.
History of hypersensitivity and anaphylactoid reactions to pneumococcal vaccine or any component of the formulation, including diphtheria toxoid
Known hypersensitivity to any of the components of cabozantinib or nivolumab
A history of sun hypersensitivity or photosensitive dermatitis.
Participants with prior use of pirfenidone or known hypersensitivity to any of the components of study treatment will be excluded from the study
Severe hypersensitivity reactions to monoclonal antibodies, known hypersensitivity to the investigational medicinal products or to one or more of the excipients, autoimmune diseases (inflammatory bowel diseases, interstitial lung disease, or pulmonary fibrosis), and live vaccines within 28 days prior to study entry.
Hypersensitivity to ipilimumab or nivolumab or any of their excipients
Known hypersensitivity to immunoglobulins or to any other component of the IP formulation
History of hypersensitivity to IP or comparator agents
Known hypersensitivity to cetuximab or other EGFR antibody
Patients with a known hypersensitivity to the olaparib, carboplatin or cabazitaxel.
History of infusion-related reactions and/or hypersensitivity to trastuzumab, (ado-)trastuzumab emtansine;
History of hypersensitivity to durvalumab or any excipient
History of hypersensitivity to Vicinium or its components
Has known hypersensitivity to baker's yeast
Previously known hypersensitivity to any of the agents used in this study; known sensitivity to busulfan or fludarabine
Hypersensitivity to nivolumab, ipilimumab, or any of its excipients
Known prior severe hypersensitivity to investigational product(s) or any component in its formulations, including known severe hypersensitivity reactions to monoclonal antibodies (NCI CTCAE v 4.03 grade >= 3).
History of severe hypersensitivity to nivolumab, cyclophosphamide, fludarabine, interleukin-2, or any excipient
History of hypersensitivity to durvalumab or any excipient
History of hypersensitivity to thyrotropin alpha (Thyrogen)
Patients must not have a known hypersensitivity to the components of niraparib or the excipients
History of hypersensitivity to the combination of durvalumab and tremelimumab.
Hypersensitivity to nivolumab or ipilimumab or any of its excipients
Patients with known hypersensitivity to perflutren
History of hypersensitivity to durvalumab or any excipient
Known hypersensitivity to Avidin or AvidinOX (e.g. hen egg)
Known hypersensitivity to ST2210 (DOTA biotin) or any excipient.
Known prior hypersensitivity to the investigational product or any component formulations, including known severe hypersensitivity reactions to monoclonal antibodies
Known hypersensitivity to pirfenidone, carboplatin, pemetrexed or paclitaxel
(Bevacizumab-related exclusion) Known hypersensitivity to any component of bevacizumab
History of hypersensitivity to durvalumab or any excipient
History of hypersensitivity to durvalumab or any excipient
Prior history of hypersensitivity to gemcitabine.
History of hypersensitivity to durvalumab or tremelimumab or any excipient
History of hypersensitivity to the combination or comparator agent (if applicable)
Patient with documented hypersensitivity to any of the components of the therapy program
Patients will not be eligible if they have a history of hypersensitivity to tranexamic acid
FOR ALL PHASES (Ib AND II): Known hypersensitivity to any of the study drugs, study drug classes, or excipients in the formulation
Patients with known prior hypersensitivity reaction to any of the study drugs
Hypersensitivity to durvalumab or tremelimumab, or any excipients on the formulation
History of hypersensitivity to durvalumab or any excipient
History of hypersensitivity to tremelimumab or any excipient
History of hypersensitivity to the combination or comparator agent
Known hypersensitivity to any of the study drugs
Documented hypersensitivity to bumetanide or sulfonamides
Has hypersensitivity to nivolumab or any other drug used in this protocol
Known allergies, hypersensitivity, or intolerance to any of the study medications, excipients, or similar compounds
Known hypersensitivity to the components of study drugs, its analogs, or drugs of similar chemical or biologic composition.
Known or suspected intolerance or hypersensitivity to IT-141 or any of the stated ingredients.
Patients with known hypersensitivity to 5-azacitdine or MK3475 or any of their excipients
Known hypersensitivity to any of the excipients of ribociclib or bicalutamide.
Patients with known hypersensitivity to any of the excipients of ceritinib (microcrystalline cellulose, mannitol, crospovidone, colloidal silicon dioxide and magnesium stearate)
History of hypersensitivity to durvalumab, tremelimumab, SGI-110, or any excipient
Known hypersensitivity to study drugs;
Known hypersensitivity to one or more of the study agents
Subject has known severe allergies, hypersensitivity, or intolerance to monoclonal antibodies or human proteins, or their excipients (refer to the latest version of the Investigator Brochure), or known sensitivity to mammalian-derived products
History of clinical hypersensitivity to GM-CSF, Interferon-alpha-2b (Merck), yeast, beef, or to any components used in the preparation of the experimental vaccine.
Only for subjects enrolled in Arm 1 - Neratinib and everolimus: history of hypersensitivity to everolimus.
Known hypersensitivity to any of the excipients of ribociclib (LEE-011)
Known prior severe hypersensitivity to investigational product or any component in its formulations, including known severe hypersensitivity reactions to monoclonal antibodies (NCI CTCAE v4.03 grade >= 3)
Subjects with known hypersensitivity to study drugs or their excipients
Known hypersensitivity to olaparib or any of the excipients of the product
History of hypersensitivity and anaphylactoid reactions to pneumococcal vaccine or any component of the formulation, including diphtheria toxoid
Known hypersensitivity to everolimus or other rapamycins (sirolimus, temsirolimus) or to its excipients
Known hypersensitivity to pomalidomide, dexamethasone, or any excipients in elotuzumab, formulation, or recombinant protein
History of hypersensitivity to durvalumab, tremelimumab, or any excipient.
Known hypersensitivity to an component of bevacizumab
Known hypersensitivity to anetumab ravtansine, study drug classes or excipients in the formulation
Known hypersensitivity or intolerance to any of the agents under investigation
Known hypersensitivity to any of the study agents used
Have known hypersensitivity to the active substance or to an excipient of the study treatments.
Known hypersensitivity to any component of the nivolumab or ipilimumab product
History of severe hypersensitivity reactions to paclitaxel or any of its excipients.
Patient has a known hypersensitivity to any of the excipients of ribociclib, aromatase inhibitors (such as letrozole) or fulvestrant
History of hypersensitivity to durvalumab (MEDI4736), tremelimumab, or any excipient
Known or suspected hypersensitivity to azacitidine or mannitol
Hypersensitivity to nivolumab or lenalidomide or any of their excipients
Known allergies, hypersensitivity, or intolerance to corticosteroids, monoclonal antibodies or human proteins, or their excipients (refer to respective package inserts or investigator's brochure), or known sensitivity to mammalian-derived products
Known hypersensitivity to any study drug used in this trial
Hypersensitivity to ruxolitinib or any of its excipients
Allergic reaction/hypersensitivity to thalidomide or to the excipients contained in the formulation of durvalumab
Known hypersensitivity to any of the excipients of ribociclib or doxorubicin
Known hypersensitivity to brentuximab vedotin components
Known severe (grade >= 3 NCI-CTCAE version [v]4.03) hypersensitivity reactions to monoclonal antibodies, including hypersensitivity to the investigational agent or any component in its formulations, or history of anaphylaxis
Known hypersensitivity to any of the study drugs or analogs
Patients with a known history of hypersensitivity to lomustine, dacarbazine, or any components of lomustine
Known hypersensitivity to afatinib or its excipients
History of hypersensitivity to paclitaxel, not attributed to a hypersensitivity type reaction to Cremophor®, or history of hypersensitivity type reaction to polysorbate 80 or other components of the formulation of Oraxol
Known hypersensitivity to immunoglobulins or any other component of the study drug
Patient has known hypersensitivity to the components of the study drugs or any analogs
History of hypersensitivity to durvalumab, tremelimumab, olaparib or, any excipient
Patient has known hypersensitivity to the components of the study drugs or their analogs
Known hypersensitivity to deferasirox
Known hypersensitivity to any component of the investigational product
Known hypersensitivity to azacitidine or mannitol
Known hypersensitivity to any study drug
History of hypersensitivity to AZD1775, irinotecan, or any excipients of these agents
Known hypersensitivity to nintedanib, gemcitabine and nab-Paclitaxel, peanut or soy or any other trial drug, their excipients
History of hypersensitivity to durvalumab or any excipient
History of hypersensitivity to cyclophosphamide, fludarabine or IL-2.
Known hypersensitivity to either study drug (umbralisib or ibrutinib)
Known hypersensitivity to S-1 or its metabolites (eg, 5-FU);
Prior hypersensitivity to bevacizumab or toxicity requiring discontinuation of bevacizumab
History of hypersensitivity to durvalumab or any excipient
Known hypersensitivity to GT0918 or its excipients.
Known hypersensitivity to any excipient contained in the brentuximab formulation
Known hypersensitivity to the study drugs or the drugs with similar chemical structures
Known hypersensitivity to any of the components of LMB-100
Participants with contra-indication and/or history of severe hypersensitivity reactions to nab-paclitaxel
Known hypersensitivity to any of the components of LMB-100
Participants with contra-indication and/or history of severe hypersensitivity reactions to nab-paclitaxel
Known hypersensitivity to one or more of the study agents
Patients with a history of hypersensitivity to bosutinib or axitinib
History of any serious adverse reaction or hypersensitivity to cytarabine, unless reaction is deemed irrelevant to the study by the Investigator and Medical Monitor
Previously known hypersensitivity to any of the agents used in this study
Subject has a known allergic/hypersensitivity to investigational components or excipients (doxorubicin, trehalose, monoclonal antibody therapy, penicillin class of antibiotics, gentamicin (or other aminoglycosides), or ciprofloxacin hydrochloride (or other quinolones)).
History of hypersensitivity to osimertinib (or drugs with a similar chemical structure or class to osimertinib) or any excipients of these agents
Known hypersensitivity to the trial drugs (volasertib and romidepsin)
Patient has hypersensitivity to brentuximab vedotin
Known or possible hypersensitivity to palbociclib, fulvestrant, goserelin (if applicable) or to any of their excipients
Known hypersensitivity to any of the excipients of ceritinib (microcrystalline cellulose, mannitol, crospovidone, colloidal silicon dioxide and magnesium stearate)
History of hypersensitivity to durvalumab or any excipient
History of hypersensitivity to paclitaxel or carboplatin or their excipients
Have known allergies, hypersensitivity, or intolerance to ARN-509 (apalutamide) or its excipients
History of hypersensitivity to durvalumab or any excipient
History of hypersensitivity to the combination or comparator agent
Known hypersensitivity to letrozole or fulvestrant, or any of its excipients, or to any palbociclib excipients
Patients with known history of hypersensitivity to paclitaxel that did not resolve with pre-medication
Known hypersensitivity to any component of ado-trastuzumab emtansine
Known hypersensitivity to the components of study drugs, its analogs, or drugs of similar chemical or biologic composition
Known hypersensitivity to exemestane or its excipients
Known hypersensitivity to nintedanib, any other trial drug, or their excipients
History of hypersensitivity to hydrogel.
Known hypersensitivity to lenalidomide, dexamethasone, any excipients in the elotuzumab formulation (sodium citrate, citric acid, sucrose and polysorbate 80) or recombinant protein
Previously known hypersensitivity to any of the agents used in this study
Known hypersensitivity to any study drug component.
Known hypersensitivity to any of the test drugs, test drug classes, or excipients in the formulation
Patient has known hypersensitivity to any of the excipients of ribociclib
History of hypersensitivity to MEDI4736 or any excipient
History of hypersensitivity to tremelimumab or the combination of MEDI4736 + tremelimumab
History of hypersensitivity of lenalidomide or thalidomide
Known hypersensitivity reactions to any of the components of Sym004
History of hypersensitivity to durvalumab or tremelimumab or any excipient
Hypersensitivity to simvastatin or ezetimibe.
Known hypersensitivity to any of the components of atezolizumab or nab-paclitaxel
Patients with known hypersensitivity to taxanes or platinums are to be excluded
Patients with known hypersensitivity to any of the excipients of ceritinib (microcrystalline cellulose, mannitol, crospovidone, colloidal silicon dioxide and magnesium stearate)
Known or possible hypersensitivity to palbociclib (CTCAE version [V] 4.03)
Patients with known hypersensitivity to the components of the study drugs or their analogs
A history of hypersensitivity to selumetinib, or any excipient agents (e.g. Captisol or TPGS- a water soluble form of Vitamin E)
Patients with a known hypersensitivity to olaparib or tremelimumab
Known sensitivity to kanamycin and other aminoglycosides; patients with known hypersensitivity to kanamycin or any other aminoglycoside antibiotic will be excluded
No known hypersensitivity to rat monoclonal antibodies
Known intolerance or hypersensitivity to rapamycin analogs (e.g. sirolimus, temsirolimus)
Has known hypersensitivity to MK-3475 (pembrolizumab) or any of its incipients
Patients with a known hypersensitivity to gemcitabine (Arm B only)
Patients with hypersensitivity to docetaxel or polysorbate 80 (Arm A only)
Known HER2 status
Subject has a known hypersensitivity to pembrolizumab or any of its ingredients
Known hypersensitivity to any component of the product (lenvatinib or ingredients).
History of hypersensitivity to lenalidomide (Part B only)
Known hypersensitivity to any of the components of talazoparib
Prior unanticipated severe reaction to fluoropyrimidine therapy or known hypersensitivity to 5–fluorouracil
History of hypersensitivity to any component of the formulation
Known hypersensitivity to afatinib or the excipients of any of the trial drugs
Has known hypersensitivity to pembrolizumab (MK-3475) or its formulation
Known hypersensitivity to S-equol or any of its excipients
Patients with a known hypersensitivity to interferon-alpha
Known intolerance or hypersensitivity to everolimus or other rapamycin analogs (e.g. sirolimus, temsirolimus)
Patients with known hypersensitivity to any of the excipients of ceritinib (microcrystalline cellulose, mannitol, crospovidone, colloidal silicon dioxide and magnesium stearate)
Known hypersensitivity to any of the study drugs
History of hypersensitivity reactions attributed to a conventional formulation of doxorubicin hydrochloride (HCL) or the components of doxil, paclitaxel, or carboplatin
Patients with known hypersensitivity to any of the excipients of ceritinib (microcrystalline cellulose, mannitol, crospovidone, colloidal silicon dioxide and magnesium stearate)
History of hypersensitivity to MEDI4736 or any excipient.
Known hypersensitivity to 5-FU injection, poor nutritional state, known dipyrimidine dehydrogenase deficiency, or taking sorivudine (such as Usevir, Bravavir, etc.)
History of hypersensitivity to active or inactive excipients of any component of treatment
Known hypersensitivity or infusion reaction to cisplatin and gemcitabine
Patients with known hypersensitivity to any of the excipients of ceritinib (microcrystalline cellulose, mannitol, crospovidone, colloidal silicon dioxide and magnesium stearate)
History of hypersensitivity to paclitaxel
Patients with documented hypersensitivity to any components of the study program
Subjects with history of hypersensitivity to azoles
Known hypersensitivity to any component of bevacizumab
Patient with documented hypersensitivity to any of the components of the chemotherapy program
Patients with a known hypersensitivity to BKM120 or to its excipients
Patients with known hypersensitivity to any of the components of PFK-158.
Known intolerance or hypersensitivity to everolimus or other rapamycin analogs (e.g. sirolimus, temsirolimus)
History of hypersensitivity to mannitol
Known hypersensitivity to thalidomide or lenalidomide
Patients with known hypersensitivity to gemcitabine or docetaxel
Patients with known hypersensitivity to pegfilgrastim and filgrastim
Known hypersensitivity to thalidomide, lenalidomide or ipilimumab
Known hypersensitivity to any component of Avastin
Known hypersensitivity to one or more of the study agents
Patients must not have previously existing hypersensitivity to brentuximab vedotin or ipilimumab
Known hypersensitivity to bevacizumab or any of its excipients or any other study drug
Patients with porphyria, or with known hypersensitivity to porphyrins or porphyrin-like compounds
Hypersensitivity of TZD
Known hypersensitivity or other serious adverse reaction to any azole antifungal therapy or to any other ingredient of the study medication used.
Subjects must not have a known history of hypersensitivity to mannitol
Known hypersensitivity to thalidomide
Known or suspected hypersensitivity to ruxolitinib.
Must not have a known or suspected hypersensitivity to azacitidine, mannitol, or compounds of similar composition to azacitidine
Known hypersensitivity or desquamating rash to either thalidomide or lenalidomide
Patients with known hypersensitivity to any excipient contained in the drug formulation.
Known hypersensitivity to 5AC or GM-CSF
Previously known hypersensitivity to any of the agents used in this study
Patient has known hypersensitivity to the components of study drug or its analogs
Any history of severe hypersensitivity reaction to docetaxel or other drugs formulated with polysorbate 80
Prior use of gossypol or AT-101, or known hypersensitivity to gossypol or AT-101
Patient with documented hypersensitivity to any of the component medications
Hypersensitivity to mithramycin
History of hypersensitivity to sirolimus, temsirolimus, everolimus
History of hypersensitivity to any component of the formulation
Patients with known hypersensitivity to the components of study drug or its analogs
History of hypersensitivity to temsirolimus or its metabolites (including sirolimus), polysorbate 80, or to any component of the formulation
History of hypersensitivity to vemurafenib
History of hypersensitivity to sorafenib for vemurafenib/sorafenib arm
History of hypersensitivity to crizotinib for vemurafenib/crizotinib arm
History of hypersensitivity to any component of the formulation
Patient with documented hypersensitivity to any of the components of the chemotherapy program
Patients with a known hypersensitivity to everolimus or other rapamycins (sirolimus, temsirolimus) or to its excipients
Known hypersensitivity to thalidomide
Have known allergies, hypersensitivity, or intolerance to abiraterone acetate, apalutamide or prednisone or their excipients
Patients with history of hypersensitivity to conductive hydrogel are not eligible
History of hypersensitivity active or inactive excipients of AZD9291 (osimertinib) or drugs with a similar chemical structure or class to AZD9291 (osimertinib)
Hypersensitivity to decitabine, guadecitabine, or any of their excipients.
Known hypersensitivity to enzalutamide or any of its components.
Patients with a history of or known hypersensitivity to melphalan or the components of the Melphalan/HDS system.
Known hypersensitivity to any component of axitinib or prior use of axitinib
Patients who are (MVF-HER-2[266-296] and MVF-HER-2 [597-626]) immediate hypersensitivity skin test positive
Patients with a known hypersensitivity to any of the study agents
Prior history of hypersensitivity reactions to oxaliplatin, bevacizumab, fluorouracil (5-FU) or capecitabine
Known hypersensitivity to thalidomide or lenalidomide
Known severe hypersensitivity to trastuzumab (excluding mild to moderate infusion reactions that are easily managed and do not recur)
Known hypersensitivity to any component of topotecan or doxorubicin or other required drugs in the study
Patients with a history of severe hypersensitivity reaction to docetaxel or other drugs formulated with polysorbate 80. Please refer to Study Appendix O for a complete list of Polysorbate 80 containing drugs.
Known hypersensitivity to thalidomide.
Known hypersensitivity to any component of the study medication(s).
Known allergies, hypersensitivity, or intolerance to the IP or its excipients
Has hypersensitivity to eribulin or any of the excipients
Allergies, hypersensitivity, or intolerance to niraparib or the corresponding excipients
Known hypersensitivity to ASN007 or its excipients;
Subjects who have a hypersensitivity to aspirin or non-steroidal anti-inflammatory drugs (NSAIDs)
Patients who have received prior treatment with a PI3K inhibitor or have known hypersensitivity to Gedatolisib or its excipients
Known hypersensitivity to docetaxel or other drugs formulated with polysorbate 80
History of hypersensitivity to durvalumab or any excipient.
hypersensitivity to the active substance or to any of the excipients of study drug;
Patients with known hypersensitivity to any of the components of MCLA-117 or who have had prior hypersensitivity reactions to human or humanized monoclonal antibodies;
Known hypersensitivity to any of the excipients of INC280
Subject has known hypersensitivity to dexamethasone, clarithromycin, lenalidomide, or thalidomide
Have a known sensitivity to any of the components of Andes-1537
Have a history of hypersensitivity reaction to any of the components of Temozolomide
Have a history of hypersensitivity to dacarbazine (DTIC)
Allergies or hypersensitivity to murine, chimeric, human or humanised proteins
Has known hypersensitivity to TAS-119 or its components.
Has known hypersensitivity to Cremophor® EL, paclitaxel or its components.
History or presence of hypersensitivity or idiosyncratic reaction to deferiprone or deferoxamine;
Patients previously treated with docetaxel for NSCLC or with known severe hypersensitivity to taxane therapies.
Patients with a known hypersensitivity to BKM120 or to its excipients
Patient with hypersensitivity to bortezomib, boron or dexamethasone
History of hypersensitivity to a taxane
Hypersensitivity to fluphenazine or other phenothiazines
Known hypersensitivity to recombinant proteins or any excipient contained in the drug formulation
Hypersensitivity to AQ4N or to any ingredients contained in the drug formulation.
Hypersensitivity to temozolomide or to any ingredients contained in the drug formulation and dacarbazine (DTIC).
Subjects to receive ofatumumab: hypersensitivity to ofatumumab or its excipients.
Known hypersensitivity to MMB, its metabolites, or formulation excipients
Steroids as premedication for hypersensitivity reactions are permitted;
Patients with a known hypersensitivity to olaparib or any of the excipients of the product.
Hypersensitivity to any reagents used in the study.
Known hypersensitivity to any study drug
Patients with a known hypersensitivity to olaparib or any of the excipients of the product
Patients with a known hypersensitivity to the testosterone cypionate or any of the excipients of the product
Known hypersensitivity to any of the components of talazoparib
Known hypersensitivity to any temozolomide component or to dacarbazine (DTIC).
Known hypersensitivity to irinotecan or its excipients.
History of hypersensitivity to cyclophosphamide, fludarabine or IL-2
Subject has known allergies, hypersensitivity, or intolerance to monoclonal antibodies or human proteins, or their excipients
Known hypersensitivity to enzalutamide
Patients with a known hypersensitivity to 5-aminolevulinic acid or any component of the study material
Known or possible hypersensitivity to fulvestrant, or palbociclib or any of their excipients.
Patients with hypersensitivity to mannitol are not eligible; patients who have known hypersensitivity to peanut or soya, any other trial drug, or their excipients, or to contrast media are not eligible
Known hypersensitivity to the components of study drugs or analogs of study drugs
Known hypersensitivity to any of the study agents
Known hypersensitivity to fluorouracil (5-FU), oxaliplatin, or other platinum agents
Known hypersensitivity to nab-paclitaxel or any of its excipients
Patients with a known hypersensitivity to olaparib or any of the excipients of the product.
History of hypersensitivity to durvalumab, guadecitabine (SGI-110) or any excipient
Subject has known allergies, hypersensitivity, or intolerance to boron or mannitol, corticosteroids, monoclonal antibodies or human proteins, or their excipients (refer to respective package inserts or Investigator's Brochure), or known sensitivity to mammalian-derived products
Patient has a known hypersensitivity to any of the excipients of BYL719 and/or enzalutamide.
Hypersensitivity to acetazolamide or sulfonamides
Patient with documented hypersensitivity to any of the components of the chemotherapy program
Has known serious hypersensitivity reactions to peg-interferon alfa-2b or interferon alfa-2b
Known hypersensitivity or intolerance to any of the agents under investigation
Known hypersensitivity to any of the components of PRI?724, fluorouracil (5?FU), oxaliplatin or bevacizumab
Patient has a known hypersensitivity to any of the excipients of BYL719 (alpelisib)
Known hypersensitivity to arsenic trioxide
History of hypersensitivity to durvalumab or any excipient
History of hypersensitivity to the combination or comparator agent (If applicable)
Known hypersensitivity to any components of study drugs
Have a known hypersensitivity to any of the components of AG-120, matched placebo, or azacitidine.
Known hypersensitivity to Cremophor®-based agents
patient has known hypersensitivity to alpelisib, fulvestrant or letrozole
Known hypersensitivity reaction to GM-CSF
Have known hypersensitivity to the active substance or to an excipient for a study treatment.
Hypersensitivity to decitabine, guadecitabine, or any of their excipients.
A known hypersensitivity to abiraterone acetate, apalutamide, and prednisone and/or any of their excipients
Known hypersensitivity to recombinant proteins, polysorbate 80 or any excipient contained in the drug or vehicle formulation for margetuximab or pembrolizumab.
Patients with a prior hypersensitivity reaction to sargramostim
Prior allergic reaction or hypersensitivity to cetuximab or MEDI4736 (durvalumab) or any of study drug excipients
The subject has a history of hypersensitivity reaction to temozolomide or a history of hypersensitivity to dacarbazine (DTIC)
Patient has hypersensitivity to bortezomib, boron, or mannitol
Patients with a known hypersensitivity to gemtuzumab ozogamicin or its parts: recombinant humanized anti-CD33 monoclonal (hP67.6) antibody, calicheamicin derivatives or other ingredients
TREATMENT: Patients with known hypersensitivity reaction to dacarbazine are ineligible to receive temozolomide
Known hypersensitivity to any of the components of tazemetostat
Known prior or suspected hypersensitivity to study drugs or any component in their formulations
History of erythema multiforme or severe hypersensitivity to prior IMiD’s such as thalidomide and lenalidomide
History of hypersensitivity to durvalumab or any excipient
Hypersensitivity to mithramycin
Known hypersensitivity to any of the test drugs, test drug classes, or excipients in the formulation
Known hypersensitivity to cetuximab or other EGFR antibody
Known hypersensitivity to inactive ingredient of bevacizumab
Known hypersensitivity to inactive ingredient of TPI 287
Known documented or suspected hypersensitivity to the components of the study drug(s) or analogs
Patients must not have a history of hypersensitivity to active or inactive excipients of AZD4547 or drugs with a similar chemical structure or class to AZD4547
Subjects who have a history of hypersensitivity to any of the study drugs or their excipients, or a history of severe hypersensitivity to any other antigen
Known hypersensitivity to ledipasvir, sofosbuvir, or formulation excipients
Patient has a known hypersensitivity to any of the excipients of buparlisib
Patient has a known hypersensitivity to ribociclib or excipients of tamoxifen
Patient has known hypersensitivity to any of the excipients of ribociclib
Known hypersensitivity to any of the study agents used
Subject has a known hypersensitivity to any of the excipients of nab-paclitaxel or BYL719/alpelisib
History of hypersensitivity to dacarbazine
Hypersensitivity to trial medications (everolimus)
Known hypersensitivity to any of the following: bortezomib, boron, mannitol
Patients with hypersensitivity to excipients of the study drug are not eligible
Hypersensitivity to any of the study medications
Patients with known hypersensitivity to temozolomide or dacarbazine are not eligible
Known hypersensitivity to any of the study drugs or any of the ingredients or excipients of these drugs (e.g., polysorbate 80), including sensitivity to benzyl alcohol
Known hypersensitivity to afatinib, dasatinib, or the excipients of any of the trial drugs
With known hypersensitivity to treosulfan or fludarabine (fludarabine phosphate)
Patients with a known hypersensitivity to everolimus or other rapamycins (e.g., sirolimus, temsirolimus) or to its excipients
Patients with a known hypersensitivity to olaparib or any of the excipients of the product; patients with known hypersensitivity cetuximab or any of the excipients of the product
Patients who have hypersensitivity to sitagliptin
Patients will be excluded if there is any history of allergic reaction(s) attributed to compounds of similar composition to temsirolimus, sorafenib, their metabolites, or any component of their formulation (including excipients and polysorbate 80); this includes hypersensitivity to macrolide antibiotics due to potential for cross-reactivity with temsirolimus
Patients with previous hypersensitivity reaction to camptothecins are excluded
Patients with known hypersensitivity to any of the components of oxaliplatin or mitomycin C
Patients with known hypersensitivity to any of the components of oxaliplatin or mitomycin C
Documented hypersensitivity to clobetasol
Patients with a known hypersensitivity to RAD001(everolimus) or other rapamycins (sirolimus, temsirolimus) or to its excipients
Known hypersensitivity to oxaliplatin, other platinum-containing compounds
Must not have known hypersensitivity to 4-aminoquinoline compound
Patients with a known hypersensitivity to BKM120, RAD001 (including other rapalogs) or their excipient
Patients with a known hypersensitivity to everolimus or other rapamycins (e.g., sirolimus, temsirolimus) or to its excipients
Patients with known hypersensitivity to anhydrous lactose, microcrystalline cellulose, croscarmellose sodium, and magnesium stearate
Systemic hypersensitivity to Montanide ISA 51 VG or any vaccine component
Systemic hypersensitivity to Montanide ISA 51 VG or any vaccine component
Previous history of hypersensitivity to bortezomib, boron, or mannitol; known hypersensitivity to the components of study drug or its analogs
Patient has hypersensitivity to VELCADE (bortezomib), boron, or mannitol
Known hypersensitivity to any component of bevacizumab or to nab-paclitaxel (paclitaxel albumin-stabilized nanoparticle formulation)
Hypersensitivity to interferon-alpha (IFN-alpha)
Hypersensitivity to interferon alfa
Suspected hypersensitivity to IFN alfa2b
Patient must not be known to have hypersensitivity to TAK-700, to TAK-700 metabolites, to bicalutamide, or to LHRH agonist
Participants with known hypersensitivity to carboplatin, paclitaxel, or formulations containing polyethoxylated castor oil (Cremophor).
Subject with known or suspected hypersensitivity to seviteronel, or any components of the formulation
Known allergies, hypersensitivity, or intolerance to any of the study medications, excipients, or similar compounds.
Contraindications or history of allergic reaction to lapatinib or to capecitabine, known dihydropyrimidine dehydrogenase deficiency, or known hypersensitivity of 5-fluorouracil
Patients with known Aspirin-Hypersensitivity triad (asthma, allergic rhinitis, ASA hypersensitivity).
Patients with known hypersensitivity to celecoxib or other NSAIDs, aspirin or sulfonamides.
Known hypersensitivity to any of the components of talazoparib
Has a history of severe hypersensitivity reaction (e.g. generalized rash/erythema, hypotension, bronchospasm, angioedema or anaphylaxis) to pembrolizumab, gemcitabine, carboplatin, or cisplatin or their analogs and/or to any of their excipients.
Patients with a history of hypersensitivity to sirolimus or any component of the formulation.
hypersensitivity to trastuzumab, murine proteins, fulvestrant, or to any of the excipients
History of intolerance or hypersensitivity to study drug
Hypersensitivity to erlotinib or alectinib or to any of the excipients.
Subject has a history of hypersensitivity to porcine derived gelatin or collagen.
Subject has a history of hypersensitivity to microbial Transglutaminase.
Known history of immunogenicity or hypersensitivity to a CD25 antibody.
Known hypersensitivity to any of the components of RO6958688 and/or obinutuzumab
Hypersensitivity to ASTX660, excipients of the drug product, or other components of the study treatment regimen.
Known hypersensitivity to any component of the investigational products; known hypersensitivity to salicylates; known hypersensitivity to aspartame-containing products for patients with phenylketonuria; known allergies to any of the medications or components of medications used in the trial
Subject has a known hypersensitivity to any of the excipients of nivolumab, cisplatin or romidepsin
Known hypersensitivity to any study drug component
Known hypersensitivity to any of the components of niraparib or prior hypersensitivity reactions to that class of drugs.
Known hypersensitivity reaction to temozolomide or any of its components, or dacarbazine (DTIC) if enrolled on ARM 1 or irinotecan or any of its components if enrolled on ARM 2
Known severe hypersensitivity reactions to compounds similar to palbociclib or palbociclib/placebo excipients or to endocrine treatments.
Known hypersensitivity to murine or recombinant proteins, polysorbate 80, or any excipient contained in the drug formulation.
Patients must not have any known hypersensitivity to everolimus or other rapamycins (sirolimus, temsirolimus) or to its excipients
Known hypersensitivity to any excipients of tesevatinib.
Known or suspected hypersensitivity to the excipients contained in the formulation of durvalumab, lenalidomide, or dexamethasone
Known hypersensitivity to any of the GTx-024 components or subjects previously received treatment with SARM
Known intolerance/hypersensitivity to IMiDs, dexamethasone, boron or mannitol, sucrose, histidine or polysorbate 80.
Participants who had a prior exposure to trabectedin or hypersensitivity to any of the excipients will not be excluded from receiving single-agent Doxil
Known allergies, hypersensitivity, or intolerance to Doxil, dexamethasone, or their excipients
Known or suspected hypersensitivity to azacitidine or mannitol
Patients with a history of severe hypersensitivity reaction to Taxotere (docetaxel) or other drugs formulated with polysorbate 80
Has known hypersensitivity to any of the components of IP.
Have a known hypersensitivity to investigator's choice of standard of care (gemcitabine or capecitabine).
Patients must not have known hypersensitivity to irinotecan, fluorouracil, or leucovorin
Known or suspected hypersensitivity to azacitidine, mannitol, or durvalumab, its constituents, or to any other humanized monoclonal antibody.
Patient has a known hypersensitivity to any of the excipients of ribociclib
Has a history of anaphylaxis or hypersensitivity to thalidomide, lenalidomide, POM, or dex
Known hypersensitivity reaction to the GM-CSF adjuvant; Any known contra-indication to GM-CSF or Cyclophosphamide treatment;
Hypersensitivity or prior treatment with obinutuzumab
Known hypersensitivity to the study treatment or any of its ingredients.
History of severe (or known) hypersensitivity to chimeric or humanized antibodies or fusion proteins or any component of atezolizumab formulation
Have a known or suspected hypersensitivity to brigatinib or its excipients and/or crizotinib or its excipients.
Known history of immunogenicity or hypersensitivity to a CD19 antibody.
Known hypersensitivity to study drug, study drug classes or excipients of the formulation.
No known hypersensitivity to gemcitabine or nab-paclitaxel
Hypersensitivity to thalidomide, lenalidomide, pomalidomide, or dexamethasone
Intolerance or hypersensitivity to octreotide
Known or suspected hypersensitivity to azacitidine or mannitol or any other ingredient used in the manufacture of oral azacitidine (see the current azacitidine IB).
Known hypersensitivity to 5-fluorouracil/leucovorin
Known hypersensitivity to oxaliplatin or other platinum containing compounds
Known hypersensitivity to irinotecan
Have known or suspected hypersensitivity to azacitidine or any other ingredient used in the manufacturing of Azacitidine.
Known hypersensitivity to the components of the study therapy or its analogs.
Known hypersensitivity to the components of the study therapy. (Please reference Section 1, Formulation of EC1169 and EC0652, in the respective Pharmacy Manuals)
Known hypersensitivity to momelotinib, its metabolites, or formulation excipients
Known hypersensitivity to any excipient contained in the drug formulation of brentuximab vedotin or lenalidomide
Hypersensitivity to the active ingredient or any of the excipients including lactose.
Known hypersensitivity to thalidomide
For MM-2 cohort only: Hypersensitivity (eg, Rash Grade 3 or 4) to thalidomide, lenalidomide, or dexamethasone (MM-2b).
Patient has hypersensitivity to bortezomib, boron or mannitol
History of severe hypersensitivity reaction to study treatments or their excipients.
Known hypersensitivity to any of plitidepsin's formulation components
Known allergies, hypersensitivity, or intolerance to talacotuzumab and daratumumab or their excipients
Hypersensitivity to IMiDs (thalidomide or lenalidomide) defined as any hypersensitivity reaction leading to stop IMiDs within the 2 first cycles or toxicity, which does meet intolerance definition.
Known hypersensitivity to the study drugs (GS 5829, fulvestrant or exemestane), the metabolites, or formulation excipients
Known hypersensitivity to any of the study drugs or excipients
Prior treatment with or hypersensitivity to study drug or related compounds
Known hypersensitivity to any component of lenvatinib or midazolam.
Known hypersensitivity to mannitol.
Patient has a known hypersensitivity to Ribociclib or any of its excipients.
Known hypersensitivity to bicalutamide.
Known hypersensitivity to any of the study drugs or excipients
Known hypersensitivity to a component of protocol therapy
Patients with a known hypersensitivity to any excipient contained in the drug
Have known intolerance to the Test Article (ie, documented hypersensitivity AE to prior monoclonal antibody therapy, or to amatuximab or any of its excipients)
Known hypersensitivity to any of the components of talazoparib
Known serious reactions or hypersensitivity to any components of the UV1 vaccine or similar peptide based vaccines
Known hypersensitivity to GM-CSF
Has a known hypersensitivity to azacitidine or mannitol
Patients with known hypersensitivity to any TZD oral agents are not eligible
Known intolerance or hypersensitivity to Everolimus or other rapamycin analogs (e.g. sirolimus, temsirolimus)
Known hypersensitivity to the trial drugs or to their excipients
History of hypersensitivity to LCI699 or to drugs of similar chemical classes.
Hypersensitivity to 5FU (fluorouracil), oxaliplatin (or other platinum agents), irinotecan (irinotecan hydrochloride) (or to their excipients)
Known hypersensitivity to afatinib or letrozole or the excipients of any of the trial drugs.
History of hypersensitivity to any of the additives in the alectinib and crizotinib drug formulation
Previously known hypersensitivity to any of the agents used in this study
Known hypersensitivity to any study drug component including thapsigargin derivatives, polysorbate 20, or propylene glycol
Known hypersensitivity to one or more of the study agents
Known hypersensitivity to any study drug
Known hypersensitivity to any of the components of talazoparib
Known hypersensitivity to the components of niraparib
Patients with a known hypersensitivity to any excipient contained in the drug formulation
Patient has hypersensitivity to VELCADE (bortezomib), boron, or mannitol
History of hypersensitivity to anakinra.
History of hypersensitivity to denosumab.
History of hypersensitivity to everolimus.
History of hypersensitivity to any component of the formulation.
Patients must not have hypersensitivity to bortezomib, boron or mannitol
Subject has a known hypersensitivity to monoclonal antibodies or to agents of similar biologic composition as IMC-CS4.
Previously known hypersensitivity to any of the agents used in this study
Patients with a known hypersensitivity to any component of bevacizumab are not eligible for this trial
Have a history of hypersensitivity to any study drugs or their excipients, or intolerance to hydration due to preexisting pulmonary or cardiac impairment, or intolerance to opioid pain medications, or a history of severe hypersensitivity to any other antigen.
Known prior clinically relevant hypersensitivity reaction to thalidomide, including the development of erythema nodosum if characterized by a desquamating rash
Patients with known hypersensitivity to any of the components of an investigational treatment will be excluded from participation in the corresponding arm but are eligible for participation in other study arm; Patients that have a history of hypersensitivity to rapamycin derivatives will be excluded from participation in the everolimus arm
Steroids for the treatment of hypersensitivity or transfusion reactions, nausea/vomiting or pain
Patient has a known hypersensitivity to any of the excipients of ribociclib or letrozole
Patients with known hypersensitivity to any oligodeoxynucleotide.
Participant has known allergies, hypersensitivity, or intolerance to imetelstat or its excipients
Known hypersensitivity to recombinant proteins, polysorbate 80, or any excipient contained in the drug or vehicle formulation for MGA271 or pembrolizumab.
Known intolerance or hypersensitivity to everolimus or other rapamycin analogs (e.g. sirolimus, temsirolimus)
Known intolerance or hypersensitivity to progesterone or its excipients
History of hypersensitivity to castor oil
Patients with a history of severe hypersensitivity reaction to Taxotere or other drugs formulated with polysorbate 80
Known hypersensitivity to 5-fluorouracil or known dihydropyrimidine dehydrogenase (DPD) deficiency
Known hypersensitivity to capecitabine, fluorouracil, or any component of the formulation
Patients with a known hypersensitivity to ribociclib or everolimus or to its excipients.
Known allergies, hypersensitivity, or intolerance to any form of heparin or azacitidine
History of hypersensitivity to durvalumab or any excipient
Prior treatment with nintedanib (BIBF1120); known hypersensitivity to nintedanib, peanut or soya or any other trial drug, their excipients or to contrast media
History of hypersensitivity to active or inactive excipients of AZD2014 or drugs with a similar chemical structure or class to AZD2014
History of hypersensitivity to ibrutinib
History of hypersensitivity to durvalumab or any excipient
History of hypersensitivity to TPIV200
Known hypersensitivity reaction to the GM-CSF adjuvant
Hypersensitivity to pegfilgrastim or Escherichia (E.) coli derived proteins
Subjects who have a history of hypersensitivity to any of the study drugs or their excipients, or a history of severe hypersensitivity to any other Antigen.
Known hypersensitivity to ibrutinib or any component of the ibrutinib formulation
No known hypersensitivity to BIBF 1120, to its excipients or to contrast media
Known hypersensitivity to thalidomide or lenalidomide
Participant has a known or suspected hypersensitivity to azacitidine, mannitol, or any other ingredient used in the manufacture of CC-486 (see the Azacitidine IB).
Known hypersensitivity to murine or chimeric antibodies or proteins
Known hypersensitivity to any of the study drugs
Known hypersensitivity to enzalutamide or related compounds
Known prior severe allergic/hypersensitivity to the chemotherapy or any of the components of the study treatment
Known history of hypersensitivity to active or inactive excipients of HM61713 or drugs with a similar chemical structure of HM61713
Contraindication to any required concomitant drugs or supportive therapies including hypersensitivity to all anticoagulation and antiplatelet options or hypersensitivity to acyclovir or similar anti-viral drug
Patient has hypersensitivity to bortezomib, boron, or mannitol
Has known hypersensitivity to paclitaxel
Patient has a known hypersensitivity to LEE011 or any of its excipients
Has known hypersensitivity to fluorouracil (5FU), oxaliplatin, or other platinum agents.
Known hypersensitivity to acyclovir or similar anti-viral drug
History of hypersensitivity to any excipients in the investigational product.
Known hypersensitivity to any of the study drugs, study drug classes, or excipients in the formulation
Known hypersensitivity to the study drugs or excipients of the preparations or any agent given in association with this study.
Known hypersensitivity to thalidomide
Known hypersensitivity to ibrutinib
No known severe hypersensitivity reactions to compounds similar to palbociclib or palbociclib excipients or to endocrine treatments.
Known intolerance or hypersensitivity to everolimus or other rapamycin analogs (e.g. sirolimus, temsirolimus)
Patient has a known hypersensitivity to any of the excipients of BYL719
Subject has a known hypersensitivity to paclitaxel or to other drugs formulated with polyethoxylated castor oil (Cremophor).
Subject has a known hypersensitivity to platinum compounds.
Known hypersensitivity to thalidomide or lenalidomide
Hypersensitivity to chlorambucil, obinutuzumab, or venetoclax or to any of the excipients
Known hypersensitivity to everolimus or bendamustine
Known hypersensitivity to trial drug
Known hypersensitivity to any of the study drugs
Patients with a known hypersensitivity to BKM120 or to its excipients
Patients with known hypersensitivity to olaparib, AZD5363, AZD2014 or any of their excipients; patients with a history of hypersensitivity to drugs with a similar chemical structure or class to olaparib, AZD5363, or AZD2014
History of severe hypersensitivity reaction (>= grade 3) to polysorbate 80 containing drugs
Known hypersensitivity to thalidomide or lenalidomide
Known hypersensitivity to any of the components of ipilimumab, bevacizumab, or nab-paclitaxel
Documented hypersensitivity to any of the drugs used in the protocol
Known hypersensitivity to any of the study drugs or excipients
Subject has a known hypersensitivity to paclitaxel or to other drugs formulated with polyethoxylated castor oil (Cremophor).
Subject has a known hypersensitivity to platinum compounds.
Known intolerance or hypersensitivity to vitamin E, everolimus or to rapamycin derivatives
Have a known or suspected hypersensitivity to brigatinib or its excipients.
Subjects with known hypersensitivity to any of the components of AG-120.
Patients with a known hypersensitivity to BKM120 or its excipients
Patients with a history of grade >= 3 hypersensitivity reaction to trastuzumab, OR grade >= 1 with the most recent trastuzumab infusion before study entry, OR continued requirement for prolonged trastuzumab infusions to prevent hypersensitivity reactions are not eligible for participation
Have known allergies, hypersensitivity, or intolerance to AA or prednisone or their excipients
Known hypersensitivity to 5-fluorouracil/leucovorin
Known hypersensitivity to capecitabine
Known hypersensitivity to oxaliplatin or other platinum containing compounds
Known hypersensitivity to irinotecan
Known hypersensitivity to any component of bevacizumab
Known hypersensitivity to regorafenib
Subjects with hypersensitivity to study drugs or their excipients
Hypersensitivity to ofatumumab or its excipients
Known hypersensitivity to any of the study treatments or to excipients of recombinant human or humanized antibodies
Known hypersensitivity to any immunomodulatory drugs (IMiDs), including Grade 4 rash
Known hypersensitivity or intolerance to dexamethasone
Hypersensitivity to thalidomide, lenalidomide, or dexamethasone (such as Steven Johnson Syndrome). Hypersensitivity, such as rash, that can be medically managed is allowable
History of hypersensitivity to active or inactive excipients of olaparib or abiraterone or drugs with a similar chemical structure or class to olaparib or abiraterone.
Hypersensitivity to any of the study medications or any of the ingredients or excipients of these medications, including hypersensitivity to benzyl alcohol
Known hypersensitivity to acyclovir or similar anti-viral drug
Have known allergies, hypersensitivity, or intolerance to abiraterone acetate or prednisone or their excipients
Known hypersensitivity to pembrolizumab or another mAb.
Known hypersensitivity to both allopurinol and rasburicase
History of hypersensitivity to any compound in the tetracycline antibiotics group
Steroids for the treatment of hypersensitivity or transfusion reactions.
Known or suspected hypersensitivity to azacitidine or mannitol
Patients with a known hypersensitivity to olaparib or any of the excipients of the product.
Prior history of infusion reactions or hypersensitivity to any of the study drugs
Participants who have known hypersensitivity to any component of loperamide or budesonide
Hypersensitivity to previous lenalidomide or thalidomide
Have known allergies, hypersensitivity, or intolerance to enzalutamide or their excipients
Have known allergies, hypersensitivity, or intolerance to abiraterone acetate or prednisone or their excipients
Patients with a known hypersensitivity to pazopanib or topotecan or to their excipients
Subjects with known hypersensitivity to any of the components of AG-221.
Patients with a known hypersensitivity to any component of bevacizumab are not eligible for participation
Known hypersensitivity to RAD001 or other rapamycins (sirolimus, temsirolimus, deforolimus)
Patients with a known hypersensitivity to tacrolimus
Known hypersensitivity to bortezomib, boron, or mannitol
Patient with known hypersensitivity to any of the excipients of LDK378 (microcrystalline cellulose, mannitol, crospovidone, colloidal silicon dioxide and magnesium stearate)
Patient with a history of severe hypersensitivity reaction to pemetrexed or docetaxel or any known excipients of these drugs.
Patients with a known hypersensitivity to BKM120 or to its excipients, or hypersensitivity to cetuximab
Patients with a known hypersensitivity to everolimus or other rapamycins (e.g., sirolimus, temsirolimus) or to its excipients
Known anaphylactic or severe hypersensitivity to the study drugs or their analogs
Have known allergies, hypersensitivity, or intolerance to abiraterone acetate or prednisone or their excipients
History of intolerance, including Grade 3 to 4 infusion reaction or hypersensitivity to trastuzumab or murine proteins or any components of the product
Known hypersensitivity to thalidomide
Known allergies, hypersensitivity or intolerance to abiraterone acetate, prednisone or degarelix
History of hypersensitivity to ipilimumab
History of hypersensitivity to lenalidomide
Known anaphylactic or severe hypersensitivity to dasatinib or crizotinib or their analogs
Known hypersensitivity to thalidomide, lenalidomide or rituximab; including the development of erythema nodosum if characterized by a desquamating rash while taking thalidomide
Known hypersensitivity to bortezomib, boron, or any of the other agents utilized in this protocol
Hypersensitivity to one of the trial drugs or the excipients.
Known hypersensitivity to Cremophor EL. However, participants are eligible if they have had a prior paclitaxel reaction, but subsequently tolerated the drug at rechallenge.
Known hypersensitivity to protein bound paclitaxel
Known hypersensitivity to mTOR inhibitors, e.g., sirolimus (rapamycin).
Known severe hypersensitivity to tadalafil or any of the excipients of this product
Hypersensitivity to thalidomide, lenalidomide or pomalidomide
Known or suspected hypersensitivity to the excipients contained in the study drug formulation.
Known hypersensitivity to thalidomide or lenalidomide (if applicable)
Patient has hypersensitivity to bortezomib, boron, or mannitol
Patients with known hypersensitivity to rapamycins
Known hypersensitivity to brentuximab vedotin, bendamustine, or mannitol
No known hypersensitivity to 4-aminoquinoline compound
No known prior hypersensitivity to carboplatin, paclitaxel, bevacizumab or hydroxychloroquine or any of their components
Patients with hypersensitivity to any tetracyclines
Known hypersensitivity to any components of the treatments
Any concern for hypersensitivity to pazopanib, gemcitabine or docetaxel
Patients with previous hypersensitivity reactions to the study drugs and components (ex: podophyllum and povidone).
Known hypersensitivity to thalidomide or lenalidomide.
Known hypersensitivity to any excipient contained in the drug formulation of brentuximab vedotin or any component of ABVD
Patients with a known hypersensitivity to everolimus (RAD001) or other rapamycins (sirolimus, temsirolimus) or to its excipients
Known anaphylactic or severe hypersensitivity to study drugs or their analogs
Known hypersensitivity to thalidomide or lenalidomide
Known or suspected hypersensitivity to 5-azacitidine, romidepsin, mannitol or other agents used in this study
No known hypersensitivity to ofatumumab, humanized antibodies or chemotherapy agents throughout the protocol
Known hypersensitivity to capecitabine, temozolomide, or any component of the formulation and or a known deficiency of dihydropyrimidine dehydrogenase
Known hypersensitivity to any component of bevacizumab
The patient has known hypersensitivity to bovine proteins
Hypersensitivity to one or more of the TL-118 active components
Patients who have had a hypersensitivity reaction to polyoxyethylated or hydrogenated castor oil
Hypersensitivity to propranolol, or beta-blockers
Known hypersensitivity to thalidomide
Known hypersensitivity to any component of bevacizumab
History of hypersensitivity reactions to any components of the treatment regimen
Patients with a known hypersensitivity to any excipient contained in the drug formulation
Known hypersensitivity to thalidomide.
Known hypersensitivity to any component of the trial agents
Known hypersensitivity to any component of the formulation
Any known hypersensitivity to ofatumumab or its components.
Hypersensitivity to acyclovir or similar anti-viral drug
Hypersensitivity to boron or mannitol, or compounds containing these components
Known hypersensitivity to cetuximab or other EGFR antibody
Patients with a history of severe hypersensitivity reaction to JEVTANA (cabazitaxel) or other drugs formulated with polysorbate 80
Known intolerance or hypersensitivity to everolimus or other rapamycin analogs (e.g. sirolimus, temsirolimus)
Known hypersensitivity to any component of bevacizumab
Known hypersensitivity to any of the study agents used
Known hypersensitivity to thalidomide or lenalidomide.
Known hypersensitivity to any of the study agents
Patients with known hypersensitivity to recombinant proteins or any excipient contained in the drug formulation that includes trehalose, sodium citrate, and polysorbate 80
Known hypersensitivity to any of the following: diphtheria toxoid, neomycin, polymyxin B, streptomycin, 2 phenoxyethanol, formaldehyde, aluminum hydroxide, yeast
Patient has known hypersensitivity to the components of study drug or its analogs
E 16. History of hypersensitivity to docetaxel, or polysorbate 80.
Patients with a known hypersensitivity to everolimus or other rapamycins (e.g., sirolimus, temsirolimus) or to its excipients
Patients with a known hypersensitivity to vinorelbine or to its excipients
Known hypersensitivity to any of the components of MM-302 or who have had hypersensitivity reactions to fully human monoclonal antibodies
Known hypersensitivity to any of the study drugs, study drug classes, or excipients in the formulation
Known hypersensitivity to fluoropyrimidines or cisplatin.
Patients with a known hypersensitivity to RAD001 (everolimus) or other rapamycins (sirolimus, temsirolimus) or to its excipients
Known hypersensitivity to somatostatin analogues or any component of the pasireotide or octreotide long-acting release [LAR] formulations
History of hypersensitivity to sirolimus
History of hypersensitivity to vorinostat
History of hypersensitivity to hydroxychloroquine
History of hypersensitivity to any component of the formulation
Prior carboplatin or cisplatin hypersensitivity reaction
For Part C, have a known hypersensitivity to sorafenib or its excipients
Patient has known hypersensitivity to thalidomide
Known hypersensitivity to thalidomide
Known hypersensitivity to any component of bevacizumab
CARBOPLATIN ARM: hypersensitivity to carboplatin or any component of the formulation
PACLITAXEL ARM: hypersensitivity to paclitaxel or any component of the formulation
SORAFENIB ARM: history of hypersensitivity to sorafenib or any component of the formulation
Patient has hypersensitivity to bortezomib, boron or mannitol
Any history of adverse reaction or hypersensitivity to LDAC
Known hypersensitivity to thalidomide, lenalidomide, azacitidine, or mannitol
Known hypersensitivity to any component of bevacizumab
Known hypersensitivity to thalidomide
Known intolerance to either of the study drugs (or any of the excipients)
History of hypersensitivity to durvalumab, tremelimumab or any excipient
Known hypersensitivity to any components of pracinostat, azacitidine, or mannitol
Known history of hypersensitivity to aromatase-inhibitor drugs
Patients with known hypersensitivity to any oligodeoxynucleotide that cannot be adequately managed with appropriate prophylaxis; e.g. steroids.
Has a known hypersensitivity to the components of the study treatment or its analogs.
Prior treatment with or have known hypersensitivity to AL3818.
b. Indication B- LMS: Prior treatment with or have known hypersensitivity to dacarbazine.
c. Indication C - SS: Prior treatment with or have known hypersensitivity to dacarbazine.
History of hypersensitivity to durvalumab or any excipient
History of hypersensitivity to tremelimumab
Known allergies, hypersensitivity, or intolerance to TRC253 or its excipients.
Has known hypersensitivity to baker's yeast
Known hypersensitivity to cyclophosphamide, its metabolites or any other components, or known urinary outflow obstruction.
Known hypersensitivity to any component of the investigational product (PVX-410, durvalumab, or any excipient)
Known intolerance to any of the study drugs (or any of the excipients)
Known hypersensitivity to any component of bevacizumab and osimertinib
History of hypersensitivity to gemcitabine
History of hypersensitivity to nab-paclitaxel or paclitaxel
Known hypersensitivity to sirolimus.
Known hypersensitivity to docetaxel, fluorouracil (5-FU)
Patients with known hypersensitivity to any component of bevacizumab
Patient has a known hypersensitivity to the components of study drugs, its analogues, or drugs of similar chemical or biologic composition
Known hypersensitivity to thalidomide or lenalidomide (if applicable)
Hypersensitivity to bortezomib, boron, or mannitol
Known or suspected hypersensitivity to azacitidine or mannitol
Patients with a history of severe hypersensitivity reaction to Taxotere® or other drugs formulated with polysorbate 80
No history of hypersensitivity to bortezomib, boron or mannitol
History of Grade ? 3 infusion-associated AEs or hypersensitivity to another monoclonal antibody, or known hypersensitivity to diphenhydramine or acetaminophen
Known hypersensitivity to nab-paclitaxel or to gemcitabine or to any of the excipients.
Subject has known history of serious hypersensitivity reaction to a known ingredient of ASP8273, erlotinib or gefitinib.
Prior treatment with TAS4464 or known hypersensitivity to any of its inactive ingredients or drugs similar in class
Known history of ? Grade 3 hypersensitivity to a therapeutic antibody.
Prior severe reaction to fluoropyrimidines, known dihydropyrimidine dehydrogenase deficiency (DPD), or other known hypersensitivity to active substances, including fluorouracil (5-FU), or ruxolitinib, or any of their excipients.
Known hypersensitivity or intolerance to any of the active substances or excipients in the formulations for idelalisib, obinutuzumab, or chlorambucil
Have known hypersensitivity to thalidomide or lenalidomide
Patient has hypersensitivity to bortezomib, boron, or mannitol
History of known hypersensitivity to S. cerevisiae, bevacizumab or any component of FOLFOX or FOLFIRI; hypersensitivity skin test is required at screening to rule out allergy to S. cerevisiae
History of hypersensitivity to durvalumab or any excipient
History of hypersensitivity to the combination or comparator agent
Known hypersensitivity to filgrastim or to Escherichia coli (E. coli) derived proteins
Subject has known history of serious hypersensitivity reaction to ASP8273, or any component of the formulation used.
Patients with known hypersensitivity to thalidomide or lenalidomide or pomalidomide
Known hypersensitivity to any constituent of the study medication.
History of hypersensitivity to polysorbate 80
Known intolerance or hypersensitivity to everolimus or other rapamycin analogs (e.g. sirolimus, temsirolimus)
No known hypersensitivity to any of the following agents: oxaliplatin, cisplatin, capecitabine, 5-flurouracil, docetaxel, or irinotecan
Hypersensitivity to polysorbate 80
Known hypersensitivity to idelalisib, its metabolites, or formulation excipients
Known hypersensitivity to nab-paclitaxel (Arm: idelalisib + nab-paclitaxel), their metabolites, or formulation excipients
Known hypersensitivity to 5-fluorouracil, leucovorin, or oxaliplatin (Arm: idelalisib + mFOLFOX6), their metabolites, or formulation excipients
Known hypersensitivity to any component of recombinant protein production by CHO cells
Subject has a known or suspected hypersensitivity to enzalutamide or any components of the formulation used.
History of hypersensitivity to 4-aminoquinoline compound
Known hypersensitivity to mannitol
Known hypersensitivity to the trial drugs, to their excipients or to contrast media
Hypersensitivity to the active substance or ingredients of PEGPH20 and docetaxel.
Known hypersensitivity to any of the components of RO6927005
Patients with contra-indication and/or history of severe hypersensitivity reactions to gemcitabine and/or nab-paclitaxel as mentioned in the locally approved label
Patients with a known hypersensitivity to buparlisib or to its excipients
Hypersensitivity to erlotinib, crizotinib or to any of the excipients
Known hypersensitivity to afatinib (BIBW 2992) or the excipients of any of the trial drugs
Known intolerance or hypersensitivity to everolimus or other rapamycin analogs (e.g. sirolimus, temsirolimus)
Known hypersensitivity to 5-azacytidine\r\n* Prior treatment with 5-azacytidine is allowed
History of hypersensitivity to any of the study drugs or to any excipients.
Prior severe reaction to fluoropyrimidines, known dihydropyrimidine dehydrogenase deficiency (DPD), or other known hypersensitivity to active substances, including fluorouracil (5-FU), ruxolitinib, or any of their excipients.
Known hypersensitivity to dacarbazine (DTIC).
Patients with known hypersensitivity to any components of ME-344 or topotecan study drug product
History of iodine hypersensitivity
Patients with porphyria, or with known hypersensitivity to porphyrins or porphyrin-like compounds
Known hypersensitivity to any inactive ingredient of bevacizumab
Known hypersensitivity to any inactive ingredient of TPI 287
Known hypersensitivity to recombinant proteins, or any component contained in the drug formulation
Known hypersensitivity to lithium or tretinoin
Known hypersensitivity to bevacizumab or any of its excipients or any other study drug
Patient has hypersensitivity to any of the components of study drugs.
Known hypersensitivity to thalidomide or lenalidomide
Has a known hypersensitivity to cetuximab, murine proteins, or any component of cetuximab;
Has a known hypersensitivity to baker's yeast or has an active yeast infection;
Patients with known hypersensitivity to any of the components of AN-152 including doxorubicin and LH-RH agonists
History of hypersensitivity and anaphylactoid reactions to pneumococcal vaccine or any component of the formulation, including diphtheria toxoid
Subjects with known hypersensitivity to any components of ALKS 4230
Subjects with known hypersensitivity to any components of pembrolizumab (for patients in combination arm only)
Patients with hypersensitivity to amiodarone or NAC
Patients with known hypersensitivity to any of the excipients of ceritinib (microcrystalline cellulose, mannitol, crospovidone, colloidal silicon dioxide and magnesium stearate)
Patient must not have known sensitivity to terameprocol or any formulation excipients
Patients who were previously exposed and who developed severe adverse events, hypersensitivity or desquamating rash to either thalidomide or lenalidomide
Known hypersensitivity to any of the study drugs
History of hypersensitivity to IMiDs® (lenalidomide, pomalidomide, thalidomide).
Hypersensitivity to obinutuzumab
Known hypersensitivity to any of the study drugs involved
Known hypersensitivity to thalidomide or other immunomodulatory drugs.
Patients with a known hypersensitivity to everolimus or other rapamycins (sirolimus, temsirolimus) or to its excipients, or to bortezomib, boron, or mannitol
Known severe hypersensitivity to ketoconazole, calcitriol or any of the excipients of these products
Patients with known hypersensitivity or intolerance to melphalan
Known hypersensitivity to any component of study treatments that resulted in drug discontinuation
Have known allergies, hypersensitivity, or intolerance to docetaxel or dexamethasone or their excipients
Patient has a known hypersensitivity to dimethyl sulfoxide (DMSO) or murine or bovine proteins.
Known hypersensitivity to the study drugs or excipients of the preparations or any agent given in association with this study
Patients with known prior severe hypersensitivity reactions to cabazitaxel or other agents containing polysorbate 80
Patient has a known hypersensitivity to any of the excipients of PQR309.
Known hypersensitivity to any of the treatment components of ramucirumab or LY2875358.
Hypersensitivity to PEG or other component of AEB1102 (Co-ArgI-PEG)
Subjects with porphyria’s or known hypersensitivity to porphyrins
Known hypersensitivity to any component of atezolizumab formulation or other study medication
Known hypersensitivity to any component of study treatments
Known hypersensitivity to any component of study treatments
Known hypersensitivity to bendamustine or mannitol
Known hypersensitivity to the components of niraparib
Known hypersensitivity to bevacizumab or any component of its formulation
Patient has a known hypersensitivity to any of the components of the study drug.
Known hypersensitivity to thalidomide or lenalidomide (if applicable)
Known hypersensitivity to any involved study drug or any of its formulation components
No known hypersensitivity to trastuzumab or pertuzumab
Known hypersensitivity or intolerance to any of the active substances or excipients in the formulations for ENTO
Have known allergies, hypersensitivity, or intolerance to enzalutamide or niclosamide or their excipients
History of hypersensitivity to any of the study drugs or to drugs of similar chemical classes (e.g. monoclonal antibodies, polyclonal gamma globulin, polysorbates)
Known hypersensitivity to rosuvastatin
Subject has a known history of serious hypersensitivity to ASP2215, or any component of the formulation used.
Known hypersensitivity to the study investigational medicinal product (IMP), the metabolites, or formulation excipients
History of hypersensitivity (> Grade 2) to active or inactive excipients of AZD2014, drugs containing Cremophor, taxanes or structurally/chemically similar drugs
Known allergies, hypersensitivity or intolerance to prednisone or excipients of abiraterone acetate or enzalutamide. History of hypersensitivity to docetaxel or polysorbate 80.
The subject has a history of severe hypersensitivity reactions to drugs formulated with polysorbate 80;
Known hypersensitivity to the study drug or excipients of the preparation or any agent given in association with this study
Known hypersensitivity to HDAC inhibitors or to any of the components of mocetinostat
Known hypersensitivity to gemcitabine
Known hypersensitivity to any of the components of AG-221
Patients in the combination arms - known hypersensitivity to fulvestrant
Known intolerance of or hypersensitivity to fosbretabulin
Known hypersensitivity or history of severe intolerance or toxicity to study-assigned chemotherapy. Note: History of severe hypersensitivity reactions to docetaxel (polysorbate 80-based formulations) for participants to be treated with MLN4924 + docetaxel; history of hypersensitivity to carboplatin for participants to be treated with MLN4924 + carboplatin + paclitaxel; or history of severe hypersensitivity to paclitaxel (Cremophor-based formulations) for participants to be treated with MLN4924 + carboplatin + paclitaxel in Part B.
Known hypersensitivity to any excipient contained in the drug formulation of brentuximab vedotin
Known hypersensitivity to any of the treatment ingredients. Known previous Grade 3-4 infusion related reactions with anti-EGFR mABs
Known hypersensitivity to thalidomide or Revlimid (if applicable)
Known hypersensitivity to any component of study treatments that resulted in drug discontinuation
No prior history of intolerance or hypersensitivity to trastuzumab and/or adverse events related to trastuzumab, murine proteins, or any of the excipients that resulted in trastuzumab being permanently discontinued
Known hypersensitivity to any components of the study drugs
Have known hypersensitivity to platinum (Pt) compounds
Known hypersensitivity to any component of study treatments
History of hypersensitivity to hydrogel
Patients with known hypersensitivity to any of the components of romidepsin or who have had hypersensitivity reactions to paclitaxel
Known hypersensitivity to the study drug or excipients of the preparation or any agent given in association with this study
Known hypersensitivity to thalidomide or lenalidomide
Hypersensitivity to recombinant human IL-2
Known hypersensitivity to carfilzomib
Patients with a known or suspected hypersensitivity to any of the components of OTS167.
Known hypersensitivity to any components of SC16LD6.5 study drug product.
Patient has hypersensitivity to bortezomib, boron, or mannitol
Known hypersensitivity to any of the study drugs or its excipients.
Known hypersensitivity to Tween-80, or human immunoglobulin
Known hypersensitivity to chlorambucil or any of its excipients
Known hypersensitivity to study-assigned chemotherapy
History of severe hypersensitivity reactions to docetaxel (polysorbate 80-based formulations) for patients to be enrolled in Arm 1 (MLN4924 + docetaxel), history of hypersensitivity to carboplatin for patients to be enrolled in Arm 2 (MLN4924 + paclitaxel + carboplatin), or history of severe hypersensitivity to paclitaxel (cremophor-based formulations) for patients to be enrolled in Arm 2
Known significant hypersensitivity to any components of study treatment
Have known allergies or hypersensitivity to abiraterone acetate or prednisone or their excipients
Known hypersensitivity to murine or recombinant proteins, polysorbate 80, or any excipient contained in the margetuximab drug formulation
History of intolerance (including grade 3 or 4 infusion reaction) or hypersensitivity to trastuzumab or murine proteins
Known hypersensitivity to azacitidine or mannitol
Known hypersensitivity to compounds related to orteronel or to orteronel excipients
History of hypersensitivity to amikacin or other aminoglycosides
Subjects with hypersensitivity (not renal dysfunction or eye disorder) to CDV or to CMX001 or its excipients.
Subjects with known hypersensitivity to peptide drugs, including LHRH agonists.
Patients with a known or suspected hypersensitivity to either gemcitabine or any of the components of PRI-724.
Known or suspected hypersensitivity to azacitidine or mannitol
Known hypersensitivity to any study drug
Hypersensitivity to VELCADE, boron, mannitol, or any other component of protocol therapy
Hypersensitivity of AT13387 or other components of the drug product
Known hypersensitivity to bortezomib, boron, or mannitol
Known hypersensitivity to BKM120 or to its excipients
Known hypersensitivity to NSAIDs
History of hypersensitivity to taxanes or drug formulations containing Cremophor®.
Patients with known hypersensitivity to sorafenib or any other component of sorafenib.
Known hypersensitivity to lenalidomide or thalidomide
Known or suspected hypersensitivity to 5'-azacitidine or mannitol
Known hypersensitivity to the components of niraparib, PD-1 inhibitor, or their excipients
Known hypersensitivity to the components of niraparib or excipients
Known hypersensitivity to the active substance or to any of the excipients in the vaccine
Known hypersensitivity to any of the components of PRI-724
Patients with a known hypersensitivity to everolimus or other rapamycins (sirolimus, temsirolimus) or to its excipients
Patients with hypersensitivity to carfilzomib, Velcade, boron, or mannitol.
Known hypersensitivity to varenicline
Patients with known allergies, hypersensitivity, or intolerance to abiraterone acetate or prednisone or their excipients
Known hypersensitivity to recombinant proteins, murine proteins, or any excipient contained in the drug formulation
Known hypersensitivity to thalidomide
Patient has hypersensitivity to bortezomib, boron or mannitol
Known unmanageable allergies, hypersensitivity, intolerance to monoclonal antibodies, to murine, chimeric, human proteins or their excipients
Patient has hypersensitivity to brentuximab vedotin
Known hypersensitivity to bevacizumab or any of its excipients, or any SOC drugs foreseen
Known allergies, hypersensitivity, or intolerance to trabectedin, dacarbazine, dexamethasone, or their excipients
Known allergies, hypersensitivity, or intolerance to dacarbazine does not apply
Hypersensitivity to the active substance, or any of the excipients of the eribulin drug product, or dacarbazine, (please refer to the dacarbazine prescribing information).
Hypersensitivity to thalidomide, lenalidomide, or dexamethasone
Known hypersensitivity to the study drugs
Known hypersensitivity to the study drugs
Patients with a known hypersensitivity to BKM120 or to its excipients
Known or suspected hypersensitivity to ofatumumab, bendamustine or mannitol.
Known hypersensitivity to thalidomide or everolimus (including other rapamycins, sirolimus and temsirolimus)
Suspected hypersensitivity to interferon alpha
Known history of dose-limiting hypersensitivity reactions to paclitaxel/Cremophor EL
Known hypersensitivity to polymyxin B
History of severe hypersensitivity reaction to drugs formulated with polysorbate 80
Known significant hypersensitivity to study drugs or excipients
Hypersensitivity to trial medications
Known hypersensitivity to bendamustine, mannitol, or other study-related drugs
Patients with a history of severe hypersensitivity reaction to docetaxel or other drugs formulated with polysorbate 80 are excluded from participation
Patients with a known hypersensitivity to RAD001 (everolimus) or other rapamycins (e.g., sirolimus, temsirolimus) or to its excipients
Hypersensitivity to azacitidine or mannitol
Known or suspected hypersensitivity to azacitidine or mannitol
Hypersensitivity to recombinant proteins or excipients in elotuzumab, lenalidomide, or dexamethasone.
Known severe hypersensitivity to or any of the excipients of this product.
History of allergies or known hypersensitivity to any components of melphalan or the components of the Melphalan/HDS system
Known hypersensitivity to any of the study drugs
History of hypersensitivity to docetaxel or polysorbate 80
History of hypersensitivity reactions attributed to simvastatin
History of hypersensitivity to durvalumab or any excipient
Known hypersensitivity to ibrutinib or nivolumab
Known hypersensitivity to sirolimus
Subject has known history of serious hypersensitivity reaction to ASP8273, or any component of the formulation used.
Known hypersensitivity to BGJ398, fluorouracil, oxaliplatin, irinotecan or to any of the excipients
Known hypersensitivity to any of the components of talazoparib
Known hypersensitivity to any component of RDHAP
Known hypersensitivity to microcrystalline cellulose, mannitol, crospovidone, colloidal silicon dioxide, magnesium stearate
Patients with porphyria, or with known hypersensitivity to porphyrins or porphyrin-like compounds
Known hypersensitivity to human albumin
Have known hypersensitivity to pancuronium bromide, atracurium or cisatracurium,
Have known hypersensitivity to ciprofloxacin or any member of the quinolone class of antimicrobial agents,
Patient has a known hypersensitivity to any of the excipients of BKM120
Patient has prior hypersensitivity reaction or intolerance to docetaxel or other drugs formulated with polysorbate 80
No known serious or severe hypersensitivity reaction to naloxegol or any of its excipients
Have a known hypersensitivity to olanzapine or to phenothiazines
History of hypersensitivity to other psychostimulants
Patients known to have hypersensitivity to dacarbazine (DTIC) are not eligible
Known diagnosis of hypocortisolism
Known hypersensitivity to somatostatin analogs or any component of the pasireotide long acting release (LAR) or suspension concentrate (s.c.) formulations
Have known hypersensitivity to anthracycline compounds or any excipient in NC-6300.
Known hypersensitivity to thalidomide or lenalidomide (if applicable)
Known hypersensitivity or idiosyncratic reaction to any of the study drugs (Sodium Cridanimod, megestrol acetate, lidocaine) and excipients;
Has a history of severe hypersensitivity reaction to pembrolizumab, Cisplatin or radiotherapy or their analogs
Known or suspected hypersensitivity to any of the talazoparib capsule components.
Known or suspected hypersensitivity to any of the talazoparib capsule components.
Known hypersensitivity to any component of the atezolizumab product
Known hypersensitivity to cold
History hypersensitivity to opioids.
Patient with known hypersensitivity to rocuronium, sugammadex or its components.
History of hypersensitivity or reaction to N-methyl-D-aspartate (NMDA) receptor antagonists
Prior carboplatin or oxaliplatin hypersensitivity reaction
Patient has a history of hypersensitivity to fentanyl or opioids
Major contraindications to anamorelin e.g. hypersensitivity
PATIENTS: History of hypersensitivity to haloperidol or chlorpromazine
Patients with a known hypersensitivity reaction to 5-HT3 receptor antagonists or NK1 receptor antagonists
Known hypersensitivity reaction to any component of ferric carboxymaltose
Patient has a known hypersensitivity to the administration of any prescribed oral or intravenous study medication or metabolite, including but not limited to, a history of hypersensitivity to the drugs or their components, severe renal impairment, severe bone marrow suppression, or systemic infection
Hypersensitivity to pregabalin
History of hypersensitivity to pregabalin or gabapentin
History of hypersensitivity or severe intolerance to azoles
Hypersensitivity to ginseng
Patients with known hypersensitivity to octreotide or somatostatin
Patients with known hypersensitivity to NT-I7 or any component used in the vehicle/formulation are ineligible
Patients with a history of echinocandin or fluconazole hypersensitivity are not eligible
Patients with a history of echinocandin or azole hypersensitivity are not eligible
Participants with known hypersensitivity to modafinil, armodafinil, or any of its components
Known hypersensitivity to any component of bevacizumab
Known hypersensitivity to any component of testosterone
History of hypersensitivity to all of the following antibiotics: penicillin, erythromycin, clindamycin, and any fluoroquinolone
Known or suspected hypersensitivity or intolerance to fentanyl or hydromorphone or excipients in the study medications
Known or suspected hypersensitivity to any of the constituents of the investigational product
History of hypersensitivity to any excipients in the quizartinib/placebo tablets;
Known hypersensitivity to thalidomide or lenalidomide
Known hypersensitivity to recombinant proteins, polysorbate 80, or any excipient contained in the drug or vehicle formulation for MGD009
Known hypersensitivity to ASN002 or its excipients;
Prior history of hypersensitivity to milk proteins
Patients with hypersensitivity to any tetracycline
Any known hypersensitivity to dexmedetomidine
History of hypersensitivity to haloperidol or benzodiazepine
Patients with hypersensitivity to tetracyclines
Minocycline trial only: patients with hypersensitivity to any tetracyclines
Patients with previous history of hypersensitivity to ribavirin or its components
No history of severe hypersensitivity reactions to drugs or other causes (e.g., beestings)
Known hypersensitivity to recombinant ESAs or the excipients contained within the investigational product.
Hypersensitivity to dexamethasone or corticosteroids or Equal sugar substitute
Patients with known hypersensitivity to sildenafil or other ingredients of sildenafil
Known hypersensitivity to paclitaxel, Cremophor EL, or iodinated contrast media
Subjects with a history of hypersensitivity or idiosyncratic reactions to azole agents
History of hypersensitivity to sulfur hexafluoride lipid microsphere components or to any of the inactive ingredients in Lumason
Documented hypersensitivity to any component of ranolazine (Ranexa) pills
Previous medical history of, or suspected hypersensitivity to, the Methylene Blue and/or formulations' ingredients.
Patients must not have known hypersensitivity to eflornithine or sulindac or the excipients byproducts; patients must not have experienced asthma, urticaria, or allergic-type reactions after taking aspirin or other non-steroidal antiinflammatory drugs (NSAIDs)
Patient has a known history of hypersensitivity to defibrotide or any of the excipients.
History of hypersensitivity to previous influenza vaccination or severe or moderate hypersensitivity to eggs/egg protein
History of known latex hypersensitivity
Known hypersensitivity or history of hypersensitivity to dimethylsulfoxide (DMSO)
History of hypersensitivity to previous influenza vaccination or severe or moderate hypersensitivity to eggs/egg protein
History of known latex hypersensitivity
Known allergies, hypersensitivity, or intolerance to any of the study medications.
History of hypersensitivity or idiosyncratic reactions to azoles
Patient has a known hypersensitivity to the administration of rolapitant or its excipients
Known hypersensitivity to NAC
Patients who have hypersensitivity to sitagliptin
Known hypersensitivity to cyclophosphamide or any of its metabolites
Known hypersensitivity to one or more of the study agents
Known hypersensitivity to any component of the MPDL3280A or rociletinib formulations or history or hypersensitivity to chimeric humanized antibodies or fusion proteins
History of hypersensitivity reaction to Xolair or any ingredient of Xolair
Known or suspected hypersensitivity to azacitidine, mannitol, its constituents, or to any other humanized monoclonal antibody
Known intolerance or hypersensitivity to everolimus or other rapamycin analogs (e.g. sirolimus, temsirolimus)
Patients with a known hypersensitivity to olaparib or any of the excipients of the product
Known severe hypersensitivity to paclitaxel
History of hypersensitivity to durvalumab, tremelimumab or any excipient
Known hypersensitivity to any component of the nivolumab or ipilimumab product
History of hypersensitivity to taxanes; hypersensitivity to the solvent does not preclude patient participation in this Study
History of hypersensitivity or unexpected reactions to capecitabine, other fluoropyrimidine agents, or any of their ingredients
Known allergies, hypersensitivity, or intolerance to corticosteroids, monoclonal antibodies, hyaluronidase, or other human proteins, or their excipients, or known sensitivity to mammalian-derived products
History of hypersensitivity to ribociclib or any of its components
Patients with hypersensitivity to bortezomib, boron or mannitol
Patients with hypersensitivity to bortezomib, boron or mannitol
Has suspected or known hypersensitivity to ingredients of MK-8228 (letermovir) formulations
Known intolerance or hypersensitivity to everolimus or other rapamycin analogs (e.g. sirolimus, temsirolimus);
History of any reaction or hypersensitivity likely to be exacerbated by any component of the vaccine.
History of any reaction or hypersensitivity likely to be exacerbated by any component of the vaccine
Subjects with a known hypersensitivity to calcitriol
The patient has a known hypersensitivity to Lymphazurin or Lymphoseek
Patients with known or suspected hypersensitivity to perflutren
Subject has known allergies, hypersensitivity, or intolerance to monoclonal antibodies or human proteins, or their excipients (refer to respective package inserts or investigator's brochure)
History of hypersensitivity to Definity (perflutren lipid microsphere) or Lumason
History of hypersensitivity to iodinated contrast agent
Known hypersensitivity to olaparib
Known hypersensitivity to polyethylene glycol (PEG) 300
Patients with hypersensitivity to sonazoid or one of its components
Known hypersensitivity to sulfur hexafluoride or to any component of perflutren lipid (Definity)
HEALTHY VOLUNTEER: Known hypersensitivity to UCAs
History of hypersensitivity to nickel
Known hypersensitivity to any component of perflutren lipid (Definity)
Hypersensitivity to perflutren
Hypersensitivity to the contrast agent 'Definity'
Hypersensitivity to dextran and/or modified form thereof
Known hypersensitivity to perflutren (if the patient has been exposed to perflutren in the past and had an allergic reaction)
Previous hypersensitivity reaction to LAR octreotide
Known hypersensitivity to trastuzumab or pertuzumab
Women with known cardiac shunt, pulmonary hypertension or hypersensitivity to perflutren agent
Patients with known or suspected hypersensitivity to perflutren
Patients with any known hypersensitivity to perflutren agent
Hypersensitivity to NVB or any of its excipients or to any component of AVD + BV therapy
Hypersensitivity to CBT-101, excipients of the drug product, or other components of the study treatment regimen.
Known intolerance to pritelivir and/or foscarnet or any of the excipients.
History of hypersensitivity to active or inactive excipients of AZD2014 or drugs with a similar chemical structure or class to AZD2014
Patient with a history of severe hypersensitivity reaction to the planned study treatment including gemcitabine, paclitaxel, cisplatin, carboplatin, pemetrexed or any known excipients of these drugs
Known hypersensitivity to recombinant proteins, polysorbate 80 or any excipient contained in the drug formulation for enoblituzumab
Hypersensitivity or anaphylactic reaction to any somatostatin analog or to maytansinoids
Patients with known hypersensitivity to any component of Definity micro bubble contrast
Patients with known hypersensitivity to perflutren
Patients with a contraindication to having MR imaging (e.g. pacemaker) or contrast MR administration (e.g. hypersensitivity to gadolinium or renal insufficiency above the institutional threshold for administration of contrast); patients with hypersensitivity to MR contrast may be able to participate if it has been established that premedication will mitigate the hypersensitivity reaction
Known hypersensitivity to the study drug or components of the preparation
history of hypersensitivity to iodine
Known hypersensitivity to Feraheme (ferumoxytol) or any of its components
Patients with known hypersensitivity to perflutren
The subject has a known hypersensitivity to Isosulfan Blue Dye.
Subject has intolerance or hypersensitivity to iron or dextran compounds or to SiennaXP.
Known or suspected: hypersensitivity to a prior perflutren protein-type A microspheres (OPTISON) administration
History of iodine hypersensitivity
Patients with known hypersensitivity to any of the components of PEGPH20 or cetuximab*
Known hypersensitivity to zolpidem or chemically related compounds; history of serious adverse reactions or hypersensitivity to any drug
EXCLUSION CRITERIA - FOR NORMAL HEALTHY FEMALE COHORT: Known hypersensitivity to zolpidem or chemically related compounds; history of serious adverse reactions or hypersensitivity to any drug
Known hypersensitivity to NSAIDs
Patients with known hypersensitivity including anaphylaxis to trabectedin
Known hypersensitivity to NSAIDs
Known hypersensitivity or intolerance to itraconazole or similar class agents.
Patients may not have a known hypersensitivity to any of the components of ganetespib
Hypersensitivity to Caphosol ingredients
Known hypersensitivity to gemcitabine or any component of the formulation.
Allergies and Adverse Drug Reaction a. Subjects with known hypersensitivity to excipients of Dasatinib tablets
Hypersensitivity to decitabine, SGI-110, or SGI-110 excipients.
The patient received omacetaxine or has a history of hypersensitivity.
History of hypersensitivity to iodine.
Patients with known hypersensitivity to any of the excipients of ceritinib (microcrystalline cellulose, mannitol, crospovidone, colloidal silicon dioxide and magnesium stearate), midazolam and warfarin as described in the local product information.
Patients with a history of hypersensitivity to nickel.
Known or suspected hypersensitivity to azacitidine, pembrolizumab or the excipients of any of the study drugs (including mannitol). Known or suspected hypersensitivity to monoclonal antibodies.
Prior exposure to a pyrrolobenzodiazepine (PBD)-based drug, or known hypersensitivity to rovalpituzumab tesirine or excipient contained in the drug formulation
Known hypersensitivity to tartrazine, a dye used in the ensartinib 100 mg capsule.
Known hypersensitivity to the study drug or excipients of the preparation or any agent given in association with this study
History of hypersensitivity to paclitaxel, not attributed to a hypersensitivity type reaction to Cremophor
Known hypersensitivity to protein bound paclitaxel
Known history of immunogenicity or hypersensitivity to a CD19 antibody.
